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A B S T R A C T
Background
The prevention of relapse is a major issue in the management of Crohn’s disease. Corticosteroids, the mainstay of treatment of acute
exacerbations, are not effective for maintenance of remission and its chronic use is limited by numerous adverse events. Randomised
controlled trials assessing the efficacy of oral 5-aminosalicylic acid (5-ASA) agents for maintenance of medically-induced remission in
Crohn’s disease have produced conflicting results.
Objectives
To conduct a systematic review to evaluate the efficacy and safety of oral 5-ASA agents for the maintenance of medically-induced
remission in Crohn’s disease.
Search methods
We searched MEDLINE, EMBASE, CENTRAL and the IBD Group Specialized Register from inception to 8 June 2016. We also
searched reference lists and conference proceedings.
Selection criteria
We included randomised controlled trials that compared oral 5-ASA agents to either placebo or sulphasalazine in patients with quiescent
Crohn’s disease. The trials had to have a treatment duration of at least six months.
Data collection and analysis
Two authors independently extracted data and performed the risk of bias assessment. Any disagreements were resolved by discussion
and consensus. The primary outcome measure was the occurrence of relapse as defined by the primary studies. Secondary outcomes
included time to relapse, adverse events, withdrawal due to adverse events and serious adverse events. We calculated the pooled risk
ratio (RR) and corresponding 95% confidence interval (95% CI) using a fixed-effect model. All data were analysed on an intention-
to-treat basis and drop-outs were considered to be relapses. Sensitivity analyses included an available case analysis where drop-outs
were ignored and using a random-effects model. We evaluated the overall quality of the evidence supporting the outcomes using the
GRADE criteria.
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Main results
Twelve studies (2146 participants) that compared 5-ASA to placebo were included. We did not identify any studies that compared
sulphasalazine to placebo. Seven studies were judged to be at low risk of bias. The other studies were judged to have an unclear risk
of bias for various items due to insufficient details to allow for a judgement. There was no statistically significant difference in relapse
rates at 12 months. Fifty-three per cent (526/998) of 5-ASA patients (dose 1.6 g to 4 g/day) relapsed at 12 months compared to 54%
(544/1016) of placebo patients (RR 0.98, 95% CI 0.91 to 1.07; 11 studies; 2014 patients; moderate-quality evidence). Sensitivity
analyses based on an available case analysis and a random-effects model had no impact on the results. One study found no difference
in relapse rates at 24 months. Fifty-four per cent (31/57) of 5-ASA patients (dose 2 g/day) relapsed at 24 months compared to 58%
(36/62) of placebo patients (RR 0.94, 95% CI 0.68 to 1.29, 119 patients; low-quality evidence). One paediatric study found no
statistically significant difference in relapse rates at 12 months. Sixty-two per cent (29/47) of paediatric 5-ASA patients (dose 50 mg/
kg/day) relapsed at 12 months compared to 64% (35/55) of paediatric placebo patients (RR 0.97, 95% CI 0.72 to 1.31; 102 patients;
moderate-quality evidence). There was no statistically significant difference in the proportion of patients who experienced an adverse
event, withdrawal due to adverse events or serious adverse events. Thirty-four per cent (307/900) of 5-ASA patients had at least one
adverse event compared to 33% (301/914) of placebo patients (RR 1.05, 95% CI 0.95 to 1.17; 10 studies; 1814 patients). Fourteen
per cent (127/917) of 5-ASA patients withdrew due to adverse events compared to 13% (119/916) of placebo patients (RR 1.11, 95%
CI 0.88 to 1.38; 9 studies; 1833 patients). One per cent (3/293) of 5-ASA patients had a serious adverse event compared to 0.7% (2/
283) of placebo patients (RR 1.43, 95% CI 0.24 to 2.83; 3 studies; 576 patients). Common adverse events reported in the studies
included diarrhoea, nausea and vomiting, abdominal pain, headache and skin rash.
Authors’ conclusions
We found no evidence in this review to suggest that oral 5-ASA preparations are superior to placebo for the maintenance of medically-
induced remission in patients with Crohn’s disease. Additional randomised trials may not be justified.
P L A I N L A N G U A G E S U M M A R Y
Oral 5-aminosalicylic acid drugs for maintenance of medically-induced remission in Crohn’s disease
What is Crohn’s disease?
Crohn’s disease is a chronic inflammatory disorder that can involve any part of the gastrointestinal tract. It can affect people of any
age. When people have active Crohn’s disease they experience symptoms such as abdominal pain, diarrhoea and weight loss. When
symptoms stop, people are considered to be in remission. Active Crohn’s disease can be treated by medical therapy (e.g. drugs such as
steroids, immunosuppressives or biologics) or by surgery to removed the diseased portions of the intestine. The goal of medical therapy
of Crohn’s disease is to induce remission and to maintain this remission for as long as possible.
What are 5-aminosalicylic acid (5-ASA) drugs?
5-ASA drugs are a group of compounds that are thought to treat Crohn’s disease by reducing inflammation in the gastrointestinal tract.
These drugs are often taken orally (i.e. by mouth).
What did the researchers investigate?
We studied whether oral 5-ASA maintains remission in patients with Crohn’s disease and whether it causes any harms (side effects).
We searched the medical literature extensively up to 8 June 2016.
What did the researchers find?
We found 12 studies that included a total of 2146 participants. Eleven studies including 2014 adult participants compared oral 5-
ASA to a placebo (i.e. inactive pills or tablets). One study including 132 children compared oral 5-ASA to a placebo. Eleven studies
were conducted for 12 months and one study was conducted for 24 months. Seven studies were judged to be of high quality and the
other studies were judged to be of unclear quality because insufficient details were reported to allow for a judgement about quality. The
studies with insufficient details were generally older studies that were published 20 or more years ago. A combined analysis of eleven
studies including 2014 adult participants found no difference between oral 5-ASA (at daily doses between 1.6 g to 4 g) and placebo
in the proportion of participants who remained in remission at 12 months. Similarly, a study including 161 adult participants found
no difference between oral 5-ASA (at a dose of 2 g per day) and placebo in the proportion of participants who remained in remission
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at 24 months. The study involving children found no difference between oral 5-ASA (at a daily dose of 50 mg/kg) and placebo in
the proportion of participants who remained in remission at 12 months. There does not appear to be an increased risk of side effects
in people who take oral 5-ASA compared to placebo. Common adverse events reported in the studies included diarrhoea, nausea and
vomiting, abdominal pain, headache and skin rash.
In conclusion, there is no evidence that oral 5-ASA is superior to placebo for helping people with Crohn’s disease remain in remission
that was achieved by medical therapy.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
5-ASA compared to placebo for maintenance of medically- induced remission in Crohn’s disease
Patient or population: pat ients with maintenance of medically-induced remission in Crohn’s disease
Settings:
Intervention: 5-ASA compared to placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control 5-ASA compared to
placebo
Relapse,
drop-outs classed as
relapse, grouped by
length of follow-up - 12
months
535 per 10001 525 per 1000
(487 to 573)
RR 0.98
(0.91 to 1.07)
2014
(11 studies)
⊕⊕⊕©
moderate2
Relapse,
drop-outs classed as
relapse, grouped by
length of follow-up - 24
months
679 per 10003 672 per 1000
(543 to 835)
RR 0.99
(0.8 to 1.23)
161
(1 study)
⊕⊕©©
low4,5
Relapse,
drop-outs classed as
relapse, grouped by
length of follow-up -
Pediatric
688 per 10003 736 per 1000
(591 to 914)
RR 1.07
(0.86 to 1.33)
132
(1 study)
⊕⊕⊕©
moderate6
Adverse events 329 per 10001 346 per 1000
(313 to 385)
RR 1.05
(0.95 to 1.17)
1814
(10 studies)
⊕⊕©©
low,7,8
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Withdrawals due to ad-
verse events
130 per 10001 144 per 1000
(114 to 179)
RR 1.11
(0.88 to 1.38)
1833
(10 studies)
⊕⊕©©
low8,9
Serious adverse events 7 per 10001 10 per 1000
(2 to 60)
RR 1.43
(0.24 to 8.44)
576
(3 studies)
⊕⊕©©
low10
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Control group risk comes f rom control arm of meta-analysis, based on included trials.
2 Downgraded one level due to unknown risk of bias.
3 Control group risk comes f rom control arm of the included study.
4 Downgraded one level due to unknown risk of bias.
5 Downgraded one level due to sparse data (109 events).
6 Downgraded one level due to sparse data (94 events).
7 Downgraded one level due to unknown risk of bias.
8 Downgraded one level due to unexplained heterogeneity (I2 = 55%).
9 Downgraded one level due to sparse data (246 events).
10 Downgraded two levels due to very sparse data (5 events).
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B A C K G R O U N D
Crohn’s disease is a chronic inflammatory disorder that can in-
volve any part of the gastrointestinal tract. Common symptoms
include abdominal pain, diarrhoea andweight loss. Crohn’s disease
is characterized by chronicity and recurrences. There is no cure for
Crohn’s disease.Thus, treatment is directed towards inducing and
maintaining remission, and addressing complications.
The prevention of relapse is a major issue in the management
of Crohn’s disease. Corticosteroids, the main treatment for acute
exacerbations, are not effective for maintenance of remission in
Crohn’s disease (Steinhart 2003), and long-term use of corticos-
teroids is limited by numerous adverse events.
5-aminosalicylates are a group of compounds that have long been
used in inflammatory bowel disease. The first 5-aminosalicylate
agent used in clinical practice was sulphasalazine, which is com-
posed of sulphapyridine linked by an azo bond to 5-aminosalicylic
acid (5-ASA). Sulphasalazine was first used in the 1940s as a treat-
ment for arthritis (Svartz 1942). Improvement in gastrointestinal
symptoms was noted in patients who had concurrent ulcerative
colitis leading to further use of this agent in inflammatory bowel
disease.
The majority of an oral dose of sulphasalazine reaches the colon
where the azo-bond is split by an azo reductase released by colonic
bacteria, yielding 5-ASA and sulphapyridine. Virtually all the sul-
phapyridine is absorbed from the colon whereas most of 5-ASA
remains within the colon and is excreted in the stool. Several stud-
ies have shown that 5-ASA is the active therapeutic moiety of sul-
phasalazine and that sulphapyridine acts only as a carrier molecule
to deliver 5-ASA to the colon (Azad Khan 1977; Klotz 1980;
van Hees 1980). Yet it is the sulphapyridine which is responsible
for most of the severe adverse effects of sulphasalazine (Schroder
1972). Sulphapyridine undergoes acetylation in the liver with sub-
sequent excretion in the urine. Slow acetylators show more of the
adverse effects of this component secondary to accumulation of
sulphapyridine in the blood prior to excretion in the kidneys (Das
1973).
Recognition that 5-ASA is the active ingredient of sulphasalazine
and that sulphapyridine is responsible for most of the side effects
led to several investigations of the use of 5-ASA as a single agent
for the treatment of inflammatory bowel disease. 5-ASA in an
unprotected form is, however, readily absorbed in the proximal
small intestine (Myers 1987), anddoes not reach the distal bowel in
therapeutic concentrations. There have been several formulations
of 5-ASA designed to inhibit proximal absorption and to ensure
delivery to distal sites of inflammation. There are two basic ways
in which 5-ASA can be protected: by linking it to itself or to
another carrier and by the use of slow release preparations of 5-
ASA. Different 5-ASA preparations may allow delivery of 5-ASA
to different locations in the gastrointestinal tract.
5-ASA formulations include azo compounds, mesalazine delayed-
release agents and mesalazine slow-release formulations. For azo
compounds a carrier molecule is linked to 5-ASA by an azo bond
using the same principle as sulphasalazine. Olsalazine consists of
two molecules of 5-ASA joined together whilst balsalazide is a
pro-drug in which a 5-ASA molecule is linked to 4-aminoben-
zoyl-B-alanine, an inert and biologically inactive carrier molecule.
Like sulphasalazine, the azo bond of these drugs is split in the
colon by bacterial azo-reductases, releasing 5-ASA to exert local
therapeutic activity. Mesalazine delayed-release agents (Eudragit-
coated) are coated with a resin designed to dissolve at a certain
pH. Asacol is coated with Eudragit S which dissolves above pH
7.0 to release 5-ASA in the terminal ileum and colon. Eudragit-
L coated mesalazine (Salofalk) dissolves above pH 6.0 to release
5-ASA in the terminal ileum and colon. Mesalazine slow-release
formulations include drugs such as Pentasa. Pentasa contains mi-
crogranules of 5-ASA that are individually coated with ethylcellu-
lose. The microgranules are dispersed in the gut providing a slow,
steady release of 5-ASA along the length of the intestine from the
upper small bowel to the colon.
These 5-ASA preparations were intended to avoid the adverse
side effects of sulphasalazine whilst maintaining its therapeu-
tic benefits. Several randomised controlled trials have been pub-
lished, comparing various 5-ASA agents to placebo, with con-
flicting results (De Franchis 1997; Gendre 1993; Mahmud 2001;
Sutherland 1997). Three previous meta-analyses have suggested
that 5-ASA may be beneficial for the maintenance of remission in
Crohn’s disease (Camma1997;Messori 1994; Steinhart 1994), but
in one report the only bibliographic database searched was MED-
LINE (Camma 1997), and another did not report how the quality
of included studies was assessed (Messori 1994). Furthermore, a
number of recent randomised controlled trials have beenpublished
since these meta-analyses were reported. An up to date system-
atic review using the Cochrane Collaboration format is indicated
to summarise the current evidence on the use of 5-ASA agents
for the maintenance of medically-induced remission in Crohn’s
disease. When possible, data on outcomes were pooled together
for meta-analyses. This systematic review is an update of a previ-
ously published Cochrane review (Akobeng 2005). The use of 5-
ASA agents for the prevention of recurrences following surgery for
Crohn’s disease was not the subject of this review and is covered
by a separate systematic review (Gordon 2011).
O B J E C T I V E S
1. To evaluate the efficacy of 5-ASA agents for the maintenance of
medically-induced remission in Crohn’s disease.
2. To determine adverse events associated with 5-ASA treatment
in Crohn’s disease.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials were considered for inclusion.
Types of participants
Patients of any age with Crohn’s disease in remission as defined
by a recognized Crohn’s disease activity index or endoscopy were
considered for inclusion.
Types of interventions
Trials that compared oral 5-ASA agents to placebo or sul-
phasalazine with a treatment duration of at least six months were
considered for inclusion.
Types of outcome measures
The primary outcome measure was the occurrence of clinical or
endoscopic relapse as defined by the primary studies. Secondary
endpoints included time to relapse, adverse events, withdrawals
due to adverse events and serious adverse events.
Search methods for identification of studies
A. Electronic searching
We searched the following electronic databases from inception to
8 June 2016 for relevant studies:
1. MEDLINE;
2. EMBASE;
3. CENTRAL; and
4. Cochrane IBD Group Specialized Register.
The search strategy was not limited by language (see Appendix 1).
B. Reference searching
The references of all identified studies were inspected for more
trials.
C. Abstracts of major gastroenterology meetings
A manual search of abstracts submitted to major gastroenterology
meetings (1995 to 2016) was performed in the following journals
to identify more trials:
1. Gastroenterology (American Gastroenterological Association);
2. Gut (British Society of Gastroenterology);
3. American Journal of Gastroenterology (American College of
Gastroenterology);
4. Canadian Journal of Gastroenterology (Canadian Association
of Gastroenterology);
5. Journal of Pediatric Gastroenterology and Nutrition (European
Society of Paediatric Gastroenterology, Hepatology and Nutri-
tion); and
6. Journal of Pediatric Gastroenterology and Nutrition (North
American Society of Paediatric Gastroenterology, Hepatology and
Nutrition).
D. Personal contacts
Leaders in the field were contacted to try to identify other studies.
E. Drug companies
The manufacturers of 5-ASA agents were contacted for additional
data.
Data collection and analysis
Papers (or abstracts) that appeared to be potentially relevant were
identified by two authors (DZ and JKM). The authors (DZ and
JKM), after reading the full texts, independently assessed the eligi-
bility of all trials identified using the inclusion criteria above. Dis-
agreement among authors was discussed and agreement reached
by consensus.
Quality assessment
The methodological quality of the included studies was inde-
pendently evaluated by two authors (DZ and JKM) using the
Cochrane risk of bias tool (Higgins 2011). Each trial was rated as
high, low, or unclear risk of bias for each of the following criteria:
1. Randomisation sequence generation;
2. Allocation concealment;
3. Blinding;
4. Incomplete outcome data;
5. Selective reporting; and
6. Other sources of bias.
The overall quality of the evidence supporting the primary out-
comes was evaluated using the GRADE approach (Guyatt 2008;
Schünemann 2011). Randomised trials are considered to provide
high quality evidence, but may be downgraded due to: (1) risk of
bias, (2) indirectness of evidence, (3) inconsistency (unexplained
heterogeneity), (4) imprecision (sparse data), and (5) reporting
bias (publication bias). The different quality ratings are interpreted
as the likelihood that future research would change the effect esti-
mate. Further research is unlikely to change the effect estimate if
the evidence is high quality. If the overall evidence is of moderate
quality further research may have an impact on our confidence
in the effect estimate and may change the estimate. Further re-
search is very likely to have an important impact on our confi-
dence in the estimate of effect and is likely to change the estimate
when the evidence is rated as low quality. Very low quality research
means that we are very uncertain about the finding (Guyatt 2008;
Schünemann 2011).
DATA COLLECTION
A data extraction formwas developed and used to extract informa-
tion on relevant features and results of included studies. Two au-
thors (DZ and JKM) independently extracted and recorded data
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on the predefined checklist. Extracted data included the following
items:
a. characteristics of patients: age, sex, disease distribution, disease
duration, disease activity index;
b. total number of patients originally assigned to each treatment
group;
c. intervention: type and dose of 5-aminosalicylate;
d. control: placebo, other drugs;
e. concurrent medications; and
f. outcomes: time of assessment, length of follow up, type of
Crohn’s disease activity index used, definitions of remission and
relapse, relapse rates, adverse events.
STATISTICAL ANALYSIS
The Cochrane Collaboration review manager (RevMan) software
(version 5.3.5) was used for data analysis. Patients with final
missing outcomes were assumed to have relapsed. Analyses were
grouped by length of follow-up.
Dichotomous variables
We calculated the risk ratio (RR) and corresponding 95% confi-
dence interval (CI) for dichotomous outcomes. We pooled stud-
ies for meta-analysis when patients, outcomes, and interventions
were deemed to be sufficiently similar (determined by consensus).
A fixed-effect model was used to pool data.
Heterogeneity
Heterogeneity among trial results was assessed by visual inspection
of forest plots and by calculating the Chi2 and I2 statistics. We
aimed to further investigate potential sources of heterogeneity.
Publication Bias
The possibility of a publication bias was investigated through the
construction of funnel plots (trial effects versus trial size).
Sensitivity analyses
Sensitivity analyses were conducted based on the following:
a. only including patients whose outcome is known (i.e. an avail-
able case analysis where the number of patients who completed
the study are used as the denominator); and
b. random-effects versus fixed-effect models.
We also planned to consider the effect of:
c. allocation concealment;
d. type of 5 ASA;
e. dose of 5 ASA; and
f. concurrent medications (especially immunosuppressants such as
azathioprine, 6-mercaptopurine, methotrexate, cyclosporine and
mycophenolate mofetil).
R E S U L T S
Description of studies
A literature search conducted on 8 June 2016 identified 10,137
studies. Five additional studies were identified through searching
of references. After duplicates were removed a total of 7023 re-
ports remained for review of titles and abstracts. Two authors in-
dependently reviewed titles and abstracts and 37 potentially rel-
evant reports on the use of 5-ASA agents for the maintenance of
medically-induced remission in Crohn’s disease were selected for
full text review (See Figure 1). Twenty reports of 15 studies were
excluded (See Characteristics of excluded studies). Five studies
were excluded because allocation of patients to treatment was not
random (Bresci 1991; Bresci 1994; Hanauer 1993; Lichtenstein
2009; Nakshabendi 1992). One study was excluded because the
duration of treatment was four months (Brignola 1992). Camma
1997 was excluded because it was a systematic review and Luthra
2002 was excluded because it was a commentary on a pub-
lished trial. Five studies were excluded because they compared sul-
phasalazine to placebo (Ewe 1976; Lennard-Jones 1977;Malchow
1981; Malchow 1984; Summers 1979). Schreiber 1994 was ex-
cluded because it compared 5-ASA to 4-ASA. Anthonisen 1974
was excluded the participants had active Crohn’s disease and were
not in remission.
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Figure 1. Study flow diagram.
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Eighteen reports of 12 studies involving a total of 2146 pa-
tients, were selected for inclusion (Anonymous 1990; Arber 1995;
Bondesen 1991; Cezard 2009; De Franchis 1997; Gendre 1993;
Mahmud 2001; Modigliani 1996; Prantera 1992; Sutherland
1997; Thomson 1995; Wellman 1988). All twelve included stud-
ies were randomised controlled trials that compared oral 5-ASA
agents to placebo for themaintenance ofmedically-induced remis-
sion in Crohn’s disease (see Characteristics of included studies).
None of the included studies compared 5-ASA to sulphasalazine.
The participants of eleven of the included studies were adults
(aged >18). Cezard 2009 enrolled paediatric participants (aged
< 18 years). In 10 of the studies, the duration of follow-up was
12 months (Anonymous 1990; Arber 1995; Cezard 2009; De
Franchis 1997; Mahmud 2001; Modigliani 1996; Prantera 1992;
Sutherland 1997; Thomson 1995; Wellman 1988). Gendre 1993
followed up patients at 12 and 24 months. Bondesen 1991 fol-
lowed up patients at 6 month intervals for 12 to 18 months. In
11 of the included studies, the diagnosis of Crohn’s disease was
established by conventional clinical, radiologic, endoscopic or his-
tologic criteria. Bondesen 1991 did not describe how the diagno-
sis Crohn’s disease was established. In two studies (Arber 1995;
Cezard 2009), theHarvey Bradshaw activity index (Softley-Clamp
modification) was used to measure relapse whilst the other studies
used the Crohn’s Disease Activity Index (CDAI).
Studies with 12 months follow-up
Anonymous 1990
Sample
Two hundred and forty-eight patients were randomised from eight
centres in Europe, Canada and South Africa. Patients had to be in
remission at time of entry (CDAI <150) and their disease had to
be been controlled (i.e. no steroids or stable low dose prednisone
2.5 mg/day or less) for the preceding month prior to entry. Ex-
clusion criteria included ileostomy or colostomy, obstruction, per-
foration or haemorrhage, total parental nutrition, treatment with
metronidazole, azathioprine or disodium cromoglycate, known
sensitivity to salicylates, other significant disease or unsuitability
to participate in the trial. Patients subsequently found not to meet
the inclusion criteria after randomisation were excluded from the
analysis. The age of the 206 patients (115 males, 91 females) who
were included in the per protocol analysis ranged from 16 to 75
years.
Treatment
Patients were randomised to receive either 5-ASA (Mesasal/Claver-
sal) 1.5 g/day or placebo. Only anti-diarrhoeal agents were allowed
as additional medications.
Endpoints
Patients were followed up for 12 months and were considered to
have relapsed if the CDAI became >150 and had increased 60
points from baseline. Secondary outcomes included adverse events
and withdrawal due to adverse events.
Arber 1995
Sample
Fifty-nine patients (37 men, 22 women) were recruited from 9
gastroenterology centres in Israel. All patients had proven Crohn’s
disease of at least one years duration and were in continuous remis-
sion for at least sixmonths (Harvey-Bradshaw index < 4), while be-
ing treated with only 5-ASA, sulphasalazine or no therapy. Other
exclusion criteria were not reported.
Treatment
Participants were randomised to receive eithermesalazine (Rafasal)
250 mg tablets (2 x 2 per day) (n = 28) or placebo (n = 31).
Restrictions on concomitant medications were not reported.
Endpoints
Patients were followed up for 12 months and primary trial end-
points were 1-year follow-up, or clinical relapse (rise of more than
four points on the Harvey Bradshaw index). Secondary outcomes
included adverse events and withdrawal due to adverse events.
Bondesen 1991
Sample
Two hundred and two patients were recruited from eight gastroen-
terology centres in Denmark. Patients had to have clinically inac-
tive Crohn’s disease. There were no differences between the treat-
ment groups with respect to sex, age, disease duration or location,
prior medical or surgical treatment, length of remission, CDAI at
entry or adherence with medication regimen.
Treatment
Patients were randomised to receive either 5-ASA (Pentasa) 1.5 g
twice a day (n = 101) or placebo (n = 101).
Endpoints
Patients were follow up at 6 month intervals for 12 to 18 months
and trial endpoints were relapse and adverse events.
Cezard 2009
Sample
One hundred and thirty-two paediatric patients (age < 18 years)
were recruited from 17 centres (16 from France and 1 from
Switzerland). Patients had to be diagnosedwithCrohn’s disease be-
fore the age of 16 and were in clinical remission within six months
of flare-up treatment. Exclusion criteria included previous treat-
ment with mesalazine or immunosuppressants or known hyper-
sensitivity to salicylates.
Treatment
Patients were randomised to receive either 5-ASA 50 mg/kg/day
(n = 68) or placebo (n = 64).
Endpoints
Patients were followed up for 12 months and trial endpoints in-
cluded relapse, adverse events, withdrawal due to adverse events
and serious adverse events.
Mahmud 2001
10Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s disease (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sample
Three hundred and twenty-seven patients (150 males, 177 fe-
males; age >18 years) were recruited from 3 European countries
(Ireland, United Kingdom and France). Patients were diagnosed
with Crohn’s disease within five years of entry, and had to be in
remission for at least one month prior to randomisation (CDAI <
150). Steroids, azathioprine or other immunosuppressive therapy
was not allowed within one month of the pre-study visit nor was
concomitant therapy with antibiotics for more than one month.
Other exclusion criteria included pregnancy, intending to be preg-
nant or breast feeding, clinically significant hepatic or renal insuf-
ficiency, strictures causing mechanical obstruction, fistulae, oral
or symptomatic anal Crohn’s disease, stoma or significant small
bowel disease apart from terminal ileal disease and patients with
known hypersensitivity to salicylates.
Treatment
Participants were randomised to receive either 2 g/day of 5-ASA
(Olsalazine) or placebo. No other active medication for Crohn’s
disease was allowed, but antidiarrhoeal agents were permitted.
Endpoints
Patients were followed up for a total of 12 months. The primary
endpoint of efficacy was relapse defined as a CDAI > 150 or an
increase in the CDAI score by 60 points or more from the baseline
at visit 2 (week 0), or the need for additional therapy or surgery.
Prantera 1992
Sample
One hundred and twenty-five patients (78 males, 47 females; age
range 23 to 48 years) were recruited from 8 Italian centres. All
patients were in remission (defined as a CDAI < 150) for at least
3 months, but not more than 2 years and had not taken corti-
costeroids, sulphasalazine or metronidazole for at least 3 months
or azathioprine for at least 6 months prior to entry. Other exclu-
sion criteria included intestinal strictures 12 months prior to en-
try; Crohn’s disease close to the ileum; active perianal or extrain-
testinal Crohn’s disease; internal and external fistulas; sensitivity
to aminosalicylates; and “other usual criteria for excluding partic-
ipation in a clinical trial”.
Treatment
Participants were randomised to receive either 5-ASA (Asacol) 2.4
g/day (n = 64) or placebo (n = 61). Restrictions on concomitant
medications were not reported.
Endpoints
Patients were followed up for 12 months. The primary study end-
point was clinical relapse defined as CDAI > 150 with an increase
of 100 points over the baseline. Secondary outcomes included ad-
verse events and withdrawal due to adverse events.
Sutherland 1997
Sample
Two hundred and ninety-three patients ( aged≥18 years old) were
recruited from31Canadian centres. Patients had to be in remission
(CDAI<150 andno symptoms for 30days prior to entry) andhave
reported at least two flares within the last four years, with one flare
or a recent resection within 18 months. Participants should not
have taken immunosuppressives within 90 days, corticosteroids
within 30 days or mesalamine or metronidazole within 7 days
of entry. Other exclusion criteria included total proctocolectomy,
short-bowel syndrome, three or more resections within the last
10 years, chronic perianal disease, ulcerative colitis, positive stool
tests for pathogens, parasites or Clostridium difficile toxin, drug
or alcohol abuse, hepatic, neurological, endocrine, renal or other
major systemic disease, and cancer (excluding basal or squamous
cell skin), inability to provide informed consent, and sensitivity to
salicylates.
Treatment
Patients were randomised to receive either 5-ASA (capsules of mi-
crosphere coated with ethylcellulose) 3 g/day or placebo.Other ac-
tive medications for Crohn’s disease were not allowed but codeine
and loperamide were permitted for the control of diarrhoea.
Endpoints
Patients were followed up for 12 months. The primary outcome
measure was relapse defined as CDAI >150 or an increase of at
least 60 points from baseline. Secondary outcomes included ad-
verse events, withdrawal due to adverse events and serious adverse
events.
Thomson 1995
Sample
Two hundred and seven participants (101 females, 106 males; age
range 18 to 71 years) were recruited from 7 European countries,
Canada, South Africa and Israel. Patients had to be in remission
(CDAI < 150), and have had one flare within 18 months of study
entry. Azathioprine, other immunosuppressives or corticosteroids
were not permitted within one month of entry. Other exclusion
criteria included pregnancy and previous gastrointestinal surgery
with more than 100 cm of bowel excised.
Treatment
Patients were randomised to receive either 3 g/day of 5-ASA
(Claversal/Mesasal) or placebo. Other active medications for
Crohn’s disease were not allowed with the exception of antidiar-
rhoea drugs. Short-term antibiotics were allowed for non-intesti-
nal infections.
Endpoints
Patients were followed up for 12 months. The primary outcome
measure was relapse defined as a CDAI score greater than 150
with at least a 60-point increase from the baseline index score.
Secondary outcomes included adverse events and withdrawal due
to adverse events.
Study with 24 months follow-up
Gendre 1993
Sample
One hundred and sixty-one patients (77 men, 84 women; age
range 17 to 50 years) were recruited from 16 centres in France.
All patients had been in remission (CDAI < 150) for less than
24 months prior to entry. Steroids or immunosuppressive therapy
were not permitted for at least one month before entry. Other
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exclusion criteria included curative surgery, perianal disease or
planned pregnancy.
Treatment
Patients were randomised to receive either mesalazine (Pentasa), 2
g/day (n = 80) or placebo (n = 81). Antispasmodics, antidiarrhoeal
drugs, cholestyramine and sedatives were allowed.
Endpoints
Patients were followed up for 24 months and trial endpoints in-
cluded surgery for acute complications, clinical relapse (defined as
CDAI of > 250 or a CDAI between 150 and 250 with an increase
of > 50 points from baseline), adverse events, and withdrawal due
to adverse events.
Risk of bias in included studies
The results of the risk of bias analysis are summarized in Figure 2.
Random sequence generation was rated as low risk of bias in seven
studies (Anonymous 1990; Arber 1995; Cezard 2009; Mahmud
2001; Prantera 1992; Sutherland 1997; Thomson 1995) and as
unclear risk of bias in five studies (Bondesen 1991; De Franchis
1997; Gendre 1993; Modigliani 1996; Wellman 1988). Alloca-
tion concealment was rated as low risk of bias in seven studies
(Anonymous 1990; Arber 1995; Cezard 2009; De Franchis 1997;
Prantera 1992; Sutherland 1997; Thomson 1995) and as unclear
risk of bias in five studies (Bondesen 1991;Gendre 1993;Mahmud
2001; Modigliani 1996; Wellman 1988). Blinding of participants
and personnel was judged to be adequate in 10 studies and unclear
risk of bias in two studies (Bondesen 1991; Wellman 1988). The
blinding of outcome assessors was judged to be adequate in nine
studies and unclear risk of bias in three studies (Bondesen 1991;
De Franchis 1997; Wellman 1988). Bondesen 1991 did not de-
scribe drop-outs and was rated as unclear risk of bias for incom-
plete outcome data. Mahmud 2001 was rated as unclear risk of
bias for incomplete outcome data because more patients in the
olsalazine group failed to complete the study compared to placebo
patients. Reasons for patients withdrawal were given in all studies,
though no study reported post-withdrawal data for any patient.
The percentage of randomised patients with unknown outcome
at the end of study ranged from 3% (Wellman 1988) to 34%
(Modigliani 1996; Thomson 1995). For most studies more pa-
tients in the 5-ASA arm had unknown outcomes compared to the
placebo arm, this difference ranged from 3% (Sutherland 1997)
to 16% (Mahmud 2001). See additional Table 1 for more infor-
mation. Five studies were judged to be at low risk of bias for selec-
tive reporting (Cezard 2009; Mahmud 2001; Modigliani 1996;
Thomson 1995; Wellman 1988). Six studies were judged to be at
unclear risk of bias for selective reporting for reporting on some
post hoc subgroup analyses (Anonymous 1990; Arber 1995 ; De
Franchis 1997; Gendre 1993; Prantera 1992; Sutherland 1997).
However, these subgroup analyses would generally be expected for
this type of study. Bondesen 1991 was judged to be at unclear
risk of bias for selective reporting and other bias because it was
an abstract publication that provided insufficient details to allow
a judgement. The other studies were rated as low risk of bias for
other potential sources of bias.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Effects of interventions
See: Summary of findings for the main comparison 5-ASA
compared to placebo for maintenance of medically-induced
remission in Crohn’s disease
Efficacy
Occurrence of relapse
For the main analysis, we used as the denominator the total num-
ber of patients randomised. We assumed that participants who
dropped out of the study, and on whom there were no post with-
drawal information, had relapsed during the study period. There
was no statistically significant difference in relapse rates in patients
who were followed for 12 months. Fifty-three per cent (526/998)
of 5-ASA patients relapsed at 12 months compared to 54% (544/
1016) of placebo patients (RR 0.98, 95% CI 0.91 to 1.07; 11
studies; 2014 patients; Figure 3). No significant heterogeneity was
detected for this comparison (I2 = 33%, P = 0.14). A GRADE
analysis indicated that the overall quality of the evidence support-
ing this outcome was moderate due to an unknown risk of bias in
some studies in the pooled analysis (See Summary of findings for
the main comparison). A sensitivity analysis using a random-ef-
fects model had little effect on the results (RR 0.98, 95% CI 0.88
to 1.08). There was no statistically significant difference in relapse
rates at 24 months. Sixty-eight per cent (54/80) of 5-ASA patients
relapsed at 24 months compared to 68% (55/81) of placebo pa-
tients (RR 0.99, 95% CI 0.80 to 1.23, 1 study; 161 patients). A
GRADE analysis indicated that the overall quality of the evidence
supporting this outcome was low due to an unknown risk of bias
(i.e. random sequence generation, allocation concealment and se-
lective reporting) and sparse data (109 events; See Summary of
findings for the main comparison). There was no statistically sig-
nificant difference in relapse rates at 12 months in the paediatric
study (Cezard 2009). Seventy-four per cent (50/68) of paediatric
5-ASA patients relapsed at 12 months compared to 69% (44/64)
of paediatric placebo patients (RR 1.07, 95% CI 0.86 to 1.33; 1
study; 132 patients).
Figure 3. Forest plot of comparison: 1 5-ASA compared to placebo, outcome: 1.1 Relapse, drop-outs
classed as relapse, grouped by length of follow-up.
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In further sensitivity analyses, we analysed only participants who
completed the study and ignored the dropouts (i.e. an available
case analysis). There was no statistically significant difference in
relapse rates in patients who were followed for 12 months. Thirty-
eight per cent (263/689) of 5-ASA patients relapsed at 12 months
compared to 42% (316/749) of placebo patients (RR 0.90, 95%
CI 0.79 to 1.01; 11 studies; 1438 patients). Significant hetero-
geneity was detected for this comparison (I2 = 40%, P = 0.09). A
sensitivity analysis using a random-effects model had little effect
on the results (RR 0.89, 95% CI 0.76 to 1.05). There was no sta-
tistically significant difference in relapse rates at 24 months. Fifty-
four per cent (31/57) of 5-ASA patients relapsed at 24 months
compared to 58% (36/62) of placebo patients (RR 0.94, 95% CI
0.68 to 1.29, 1 study; 119 patients). There was no statistically sig-
nificant difference in relapse rates at 12 months in the paediatric
study (Cezard 2009). Sixty-two per cent (29/47) of paediatric 5-
ASA patients relapsed at 12 months compared to 64% (35/55)
of paediatric placebo patients (RR 0.97, 95% CI 0.72 to 1.31; 1
study; 102 patients).
Time to relapse
Although the initial intention was to summarise time to relapse
using the log hazard ratio, since a relationship between treatment
and withdrawal of treatment was evident we did not consider this
further.
Safety
Adverse events
There was no statistically significant difference in the proportion
of patients who experienced at least one adverse event. Thirty-
four per cent (307/900) of 5-ASA patients had at least one ad-
verse event compared to 33% (301/914) of placebo patients (RR
1.05, 95% CI 0.95 to 1.17; 10 studies; 1814 patients; Figure 4).
Statistically significant heterogeneity was detected for this com-
parison (I2 = 55%, P = 0.02). A GRADE analysis indicated that
the overall quality of the evidence supporting this outcome was
low due to an unknown risk of bias in the studies in the pooled
analysis and unexplained heterogeneity (See Summary of findings
for the main comparison). Common adverse events reported
in the studies included diarrhoea (Anonymous 1990; Cezard
2009; Gendre 1993; Mahmud 2001; Prantera 1992; Sutherland
1997; Thomson 1995), nausea or vomiting (Anonymous 1990;
Gendre 1993; Sutherland 1997; Thomson 1995), abdominal pain
(Anonymous 1990; Prantera 1992; Thomson 1995; Wellman
1988), headache (Arber 1995; Prantera 1992; Sutherland 1997;
Wellman 1988); skin rash (Prantera 1992; Wellman 1988), con-
stipation (Anonymous 1990), bloating (Anonymous 1990), loss
of appetite (Anonymous 1990), and arthralgia (Prantera 1992).
Figure 4. Forest plot of comparison: 1 5-ASA compared to placebo, outcome: 1.5 Adverse events.
Withdrawal due to adverse events
There was no statistically significant difference in the proportion
of patients who withdrew due to an adverse event. Fourteen per
cent (127/917) of 5-ASA patients withdrew due to adverse events
compared to 13% (119/916) of placebo patients (RR 1.11, 95%
CI 0.88 to 1.38; 9 studies; 1833 patients). Statistically significant
heterogeneity was detected for this comparison (I2 = 55%, P =
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0.02). A GRADE analysis indicated that the overall quality of the
evidence supporting this outcome was low due to an unknown risk
of bias in some studies in the pooled analysis and unexplained het-
erogeneity (See Summary of findings for the main comparison).
Common adverse events leading to withdrawal included diarrhoea
(Anonymous 1990; Gendre 1993; Mahmud 2001; Sutherland
1997), headache (Anonymous 1990; Arber 1995; Sutherland
1997), nausea and vomiting (Anonymous 1990; Gendre 1993;
Sutherland 1997) and abdominal pain (Anonymous 1990).
Serious adverse events
There was no statistically significant difference in the proportion
of patients who had a serious adverse event. One per cent (3/
293) of 5-ASA patients had a serious adverse event compared to
0.7% (2/283) of placebo patients (RR 1.43, 95% CI 0.24 to 2.83;
3 studies; 576 patients). No heterogeneity was detected for this
comparison (I2 = 0%, P = 0.70). AGRADE analysis indicated that
the overall quality of the evidence supporting this outcome was
low due to very sparse data (5 events; See Summary of findings
for the main comparison). Of the three studies that reported on
serious adverse events, De Franchis 1997 reported that there were
no serious adverse events in either group. There were two serious
adverse events in the Cezard 2009 study including one interstitial
nephritis in the 5-ASA group and one interstitial pneumopathy in
the placebo group. Mahmud 2001 reported three serious adverse
events, two in the 5-ASA group and one in the placebo group.
None of these serious adverse events were thought to be related to
the study medication.
Subgroup analysis
Due to the potential impact of the unknown outcome of patients
who withdrew early on the treatment effect, we did not feel it was
valid to consider effects within subgroups.
Heterogeneity
When all dropouts are assumed to have relapsed, there was no
significant heterogeneity (I2 = 33%; P =0.14) across the 11 trials
that followed up participants for 12 months . However, there was
significant heterogeneity in the sensitivity analyses where drop-
outs were ignored (I2 = 40%; P = 0.09). Further investigations of
heterogeneity were not felt applicable given the implication of the
unknown outcomes on the treatment effect.
Funnel Plots
A funnel plot analysis for the primary outcome (relapse) provides
no convincing evidence of publication bias (see Figure 5).
Figure 5. Funnel plot of comparison: 1 5-ASA compared to placebo, outcome: 1.8 Relapse, drop-outs
classed as relapse, grouped by length of follow-up.
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D I S C U S S I O N
There is no known cure for Crohn’s disease, and the disorder is
characterised by recurrent flare-ups of symptoms. Lichtenstein
2004 demonstrated in a recent study that being in remission is
associated with improved quality of life in patients with Crohn’s
disease. Preventing relapses should, therefore, be an important goal
in the management of this disease.
Whilst a number of treatment regimens are efficacious in in-
ducing clinical remission in active Crohn’s disease, no treatment
is available that can completely prevent relapse of the disorder
(Biancone 2003). Corticosteroids, the mainstay of treatment for
active Crohn’s disease are not effective as maintenance therapy
(Steinhart 2003). Although the antimetabolites, 6-mercaptop-
urine and its prodrug, azathioprine are effective in maintaining
remission in Crohn’s disease, these drugs might cause significant
adverse events (Feagan 2003). Infliximab, a monoclonal antibody
against tumour necrosis factor, is an effectivemaintenance therapy
for patients with Crohn’s disease with or without fistulas (Hanauer
2002; Rutgeerts 1999; Sands 2004). Methotrexate is also effective
for maintenance of remission in Crohn’s disease (Feagan 2000). 5-
ASA preparations have been found to be superior to placebo for
the maintenance of remission in ulcerative colitis (Wang 2016),
but its efficacy inCrohn’s disease is controversial (Sandborn 2003).
Randomised controlled trials which compared 5-ASA agents with
placebo for the maintenance of medically-induced remission in
Crohn’s disease have yielded conflicting results (de Franchis 1997;
Gendre 1993; Mahmud 2001; Sutherland 1997). In this review,
we have summarised the findings of available randomised con-
trolled trials on the subject.
For the main analyses, we used as the denominator the total num-
ber of patients randomised, and assumed that participants who
dropped out of the study, and on whom there were no post with-
drawal information, had relapsed during the study period. This
main analysis demonstrated that, in 11 randomised controlled tri-
als where 2014 participants were followed up for 12 months, there
was no statistically significant difference between 5-ASA agents
and placebo with regard to the prevention of relapse (RR 0.98,
95% CI 0.91 to 1.07). A GRADE analysis indicates that the over-
all quality of the evidence supporting this outcome was moderate.
Sensitivity analyses using a random-effects model and an avail-
able case analysis had no impact on the results. A single paediatric
study (132 participants) did not find any difference in relapse rates
between 5-ASA and placebo treated participants (Cezard 2009).
A single study in which patients were followed up for 24 months
also did not demonstrate any statistically significant difference in
relapse rates between the two groups in either the main analysis
or sensitivity analyses. We therefore found no evidence from this
study to suggest that 5-ASA agents are superior to placebo for
maintenance of medically-induced remission in Crohn’s disease.
The primary studies had a number of limitations. The drop-out
rates in most studies were quite high and as no follow-up infor-
mation was available on these patients, we assumed in the main
analysis that drop out patients had relapsed. Exactly how this as-
sumption might have affected the results of the meta-analysis is
unclear. This highlights the importance of following-up patients
after they withdraw from a study. The assessment of disease ac-
tivity was not uniform amongst the primary studies. Whilst 10 of
the included studies used the CDAI to measure disease activity,
two studies used the Harvey Bradshaw Index (Arber 1995; Cezard
2009). The studies which used CDAI defined relapse as a CDAI
> 150 or a variable minimum rise in the CDAI score between 50
and 100 points from baseline along with a CDAI > 150.
We foundno evidence to suggest thatmore adverse events occurred
in patients on 5-ASA agents compared to placebo. Although the
reporting of adverse events was somewhat inconsistent across the
studies we were able to pool data for the proportion of patients
who experienced at least one adverse event, withdrawal due to
adverse events and serious adverse events. There was no statistically
significant differences between 5-ASA and placebo for any of these
outcomes. GRADE analyses indicate that the overall quality of the
evidence supporting these outcomes was low.
Different preparations and different doses of 5-ASA were used
in the included studies. The doses ranged from 1 g to 3 g per
day. A linear dose-response relationship has been suggested for 5-
ASA agents in the maintenance of remission in ulcerative colitis
(Hanauer 2004). None of the included studies compared different
doses of 5-ASA, and there was no evidence to suggest that stud-
ies which used higher doses of 5-ASA preparations demonstrated
greater benefits or more adverse events. There was no strong indi-
cation to suggest that more adverse events occurred in patients on
5-ASA agents compared to placebo. Future studies should report
adverse events in a more consistent manner.
We found no evidence in this review to suggest that 5-ASA prepa-
rations are superior to placebo for the maintenance of medically-
induced remission in Crohn’s disease. The use of 5-ASA agents for
the prevention of recurrences following surgery for Crohn’s dis-
ease was not the subject of this review and has been assessed in a
separate systematic review (Gordon 2011).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We found no evidence in this review to suggest that 5-ASA prepa-
rations are superior to placebo for the maintenance of medically-
induced remission in patients with Crohn’s disease. The incidence
of adverse events did not appear to be different in patients receiv-
ing 5-ASA compared with those receiving placebo.
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Implications for research
The effect sizes that were found evenwhen drop-outs were ignored
were small. Therefore it appears that additional randomised tri-
als may not be justified. Any further studies of maintenance ther-
apy for Crohn’s disease should ensure allocation concealment and
complete follow-up of patients, and include more detailed and
standardised reporting of safety results. A more uniform way of
measuring relapse should also be adopted.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Anonymous 1990
Methods Randomised, double blind, placebo-controlled multicentre trial
Participants 248 patients with clinically inactive Crohn’s disease at entry (CDAI < 150) - no age or
CD location restrictions reported
Crohn’s disease had to be ’controlled’ for at least 1 month prior to entry
Controlled described as no steroids or a stable low dose (prednisone 2.5 mg/day or less)
Interventions Oral 5-ASA (Mesasal / Claversal, Smith Kline & French company) at a dose of 1.5 g/
day (n = 125)
Placebo (n = 123)
Outcomes Primary outcome: relapse at 12 months (CDAI > 150 and an increase in CDAI of 60
points from baseline)
Secondary outcomes: adverse events, withdrawal due to adverse events
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “predetermined computer-gener-
ated list”
Allocation concealment (selection bias) Low risk Quote: “Drug supplies were centrally pack-
aged, labelled and randomized in blocks of
four according to a predetermined com-
puter-generated list”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind study
Quote: “patients were randomly allocated
to treatment with one of the following reg-
iments: 5-ASA, or matching placebo for 5-
ASA”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Patient and physician assessed outcomes
were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Drop-outs balanced across intervention
groups with similar reasons for withdrawal
Selective reporting (reporting bias) Unclear risk Although some subgroup analyses were not
prespecified these analyses would generally
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Anonymous 1990 (Continued)
be expected for this type of study
Other bias Low risk The study appears to be free of other
sources of bias
Arber 1995
Methods Randomised, double blind, placebo-controlled multicentre trial
Participants 59 patients with Crohn’s disease in continuous remission for at least 6 months - patients
could have Crohn’s disease of the small bowel, large bowel or both - no age restrictions
were reported
Remission was defined as a Harvey Bradshaw (Softley-Clamp modification) index score
of < 4
Patients could be treated with only 5-ASA or sulphasalazine within last 6 months
Interventions Oral 5-ASA (Rafassal similar to Salofalk/Claversal, Rafia Laboratory, Israel) at a dose of
1 g/day (n = 28)
Placebo (n = 31)
Outcomes Primary outcome: relapse at 12 months (increase of more than 4 points on the index
from baseline)
Secondary outcomes: adverse events, withdrawal due to adverse events
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list
Allocation concealment (selection bias) Low risk Quote: “coding and randomization were
performed by a central pharmacy that dis-
pensed the coded medicines to the partici-
pating centers”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind study
Quote: “Patients were given
coded mesalazine or placebo four tablets/
day (coated 5-ASA preparation similar to
Salofalk-Claversal)”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Patient and physician assessed outcomes
were blinded
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Arber 1995 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Drop-outs balanced across intervention
groups with similar reasons for withdrawal
Quote: “Ten patients were withdrawn from
the trial, four from the placebo group and
six from the treatment group. Among these
patients, five were withdrawn because of
noncompliance, three patients were lost to
follow-up, and one in each group had side
effects (headache) leading to withdrawal
from the study”
Selective reporting (reporting bias) Unclear risk Although some subgroup analyses were not
prespecified these analyses would generally
be expected for this type of study
Other bias Low risk The study appears to be free of other
sources of bias
Bondesen 1991
Methods Randomised, double blind, placebo-controlled multicentre trial
Participants 202 patients with clinically inactive Crohn’s disease
Interventions Pentasa 1.5g bid (n = 101)
Placebo (n = 101)
Outcomes Primary outcome: relapse at 12 to 18 months
Seconadry outcome: adverse events
Notes Abstract publication
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: ”patients were...randomized to ac-
tive drug or placebo
How blinding was achieved was not de-
scribed in abstract
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Bondesen 1991 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described
Selective reporting (reporting bias) Unclear risk Not described
Other bias Unclear risk Unclear from abstract
Cezard 2009
Methods Randomised, double-blind, placebo-controlled,multicenter trial performed in17 centres
(16 from France and 1 from Switzerland) for one year
Data was analysed following an intention-to-treat analysis
Participants Patients (N=132) under the age of 18 and diagnosed with CD before the age of 16,
according to clinical, radiological, endoscopic and histological data
Specific inclusion criteria: patients in clinical remission within six months of flare-up
treatment started prior to inclusion, with an HB score inferior to 5, ESR superior to
25mm, and normal hepatic and renal function
Specific exclusion criteria: patients were excluded if a flare-up had been treated with
mesalazine or immunosuppressants, or if they had a known hypersensitivity to salicylate
Interventions 50 mg/kg mesalazine or placebo over a 1 year period
Outcomes Primary outcome: clinical relapse (HB score greater than or equal to 5, confirmed within
two weeks) or surgery for acute complication of CD
Secondary outcome: treatment failure, defined as relapse, failure of steroid withdrawal,
side-effect intolerance requiring treatment discontinuation, worsening or aggravation of
patient’s status requiring treatment
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization sequence was generated by
a third-party
Quote: ”the randomization lists were gen-
erated by the randomization center“
Quote: ”patients were randomized by stra-
tum within each center, using randomized
blocks of two to four)
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Cezard 2009 (Continued)
Allocation concealment (selection bias) Low risk Centralized randomisation performed by a
third party
Quote: “At randomization, a chronological
treatment number was assigned to each pa-
tient and, accordingly, the treatment allo-
cated to each patient was given to the physi-
cian in charge of that patient in numbered
bottles, labeled with the protocol identi-
fication, center and stratum, patient’s ini-
tials, treatment number, batch number and
expiry date”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind study
Intervention and placebo tablets were iden-
tical
Quote: “Each allocated treatment was sent
to the physician in charge of that patient in
an individual sealed envelope”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Patient and physician assessed outcomes
were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Drop-outs were similar across intervention
groups with similar reasons for withdrawal
Low proportion of withdrawals per group
Selective reporting (reporting bias) Low risk All expected outcomes were reported
Other bias Low risk The study appears to be free of other
sources of bias
De Franchis 1997
Methods Randomized, double-blind, placebo-controlled, multicentre trial conducted at 22 insti-
tutions. Data was analysed following an intention-to-treat
Participants Specific inclusion criteria: patients with an established diagnosis of Crohn’s disease lo-
calized to the ileum, colon or both with endoscopic, radiological and/or surgical confir-
mation of disease location within 1 year prior to enrolment; if they had an acute flare-up
of the disease (CDAI > 150 and ≤ 450); if they had achieved remission with a standard
steroid-dose regiment; and if they were between 18 and 70 years of age
Specific exclusion criteria: patients who had oesophageal, gastroduodenal or jejunal local-
izations of Crohn’s disease, clinically significant bowel stenosis, fistulas requiring metron-
idazole treatment or surgery, or other active extra-intestinal manifestations requiring
steroid treatment; if they had been treated with steroids or immunosuppressants within
3 months of enrolment; if they had clinically significant hepatic, renal or haematological
disease; if they were taking H2−blockers or omeprazole; if they were allergic to salicylates;
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De Franchis 1997 (Continued)
or if they were pregnant or lactating women
Interventions Patients were evaluated for inclusion during a flare-up of Crohn’s disease and treated with
steroids according to a standard dose regimen (methylprednisolone, 1 mg/kg q.d.s with
a maximum of 60 mg q.d.s. given orally for 4-8 weeks). Those who achieved clinical
remission (CDAI <150) were entered into the study. Six tablets, administered in three
daily doses, containing either 5-ASA (Claversal) 500 mg or a placebo. Daily steroid dose
was tapered by 0.25 mg/kg every two weeks once this regiment was started
Outcomes Two outcomes were assessed:
i) clinical relapse, defined as an increase of CDAI above 150 and at least 60 points
above the value observed at achievement of remission, accompanied by an increase of at
least two of the three acute-phase reactants (ESR, alpha-1 acid glycoprotein and alpha-
2 globulins)
ii) completion of a 24-month study period without clinical relapse
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Procedure used for randomisation not de-
scribed
Quote: “randomization was done centrally
in blocks of four”
Allocation concealment (selection bias) Low risk Central randomisation
Quote: “randomization was done centrally
in blocks of four”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, randomised, placebo-con-
trolled trial
Placebo pills were identical to 5-ASA pills
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Drop-outs balanced across intervention
groups with similar reasons for withdrawal
Quote: “Seventeen patients (eight on 5-
ASA and nine on placebo) were withdrawn
from the study: 15 of them were lost to fol-
low-up, one was considered as non-com-
pliant, one required surgery for ileorectal
fistula”
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De Franchis 1997 (Continued)
Selective reporting (reporting bias) Unclear risk Although some subgroup analyses were not
prespecified these analyses would generally
be expected for this type of study
Other bias Low risk The study appears to be free of other
sources of bias
Gendre 1993
Methods Multicentre study. Described as randomised:Yes Randomisation method described:No
Described as double blind:Yes Blind method described:No Follow-ups described:Yes
Strata: High relapse risk stratum (remission for < 3months) and Low relapse risk stratum
(remission for 3 - 24 months)
Participants Inclusion criteria: Age greater than 15. CD of the small bowel, colon or both. CD in
remission < 24 months. Remission defined as CDAI <150. No steroid use in month
before trial
Interventions Oral 5-ASA vs placebo. Allocation: 80 patients allocated to 5-ASA, and 81 patients allo-
cated to placebo. Name 5-ASA: Pentasa. Manufacturer: Ferring AS, Vanlose, Denmark.
Dose: 2 g per day
Outcomes Relapse measured at: 24 months. Definition of relapse: Surgery or CDAI >250 or CDAI
between 150 and 250 but over the baseline value by >50 points
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “the study followed a randomized,
double-blind, stratified design”
Identical Pentasa and placebo tablets used
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Patient and physician assessed outcomes
were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Drop-outs balanced across intervention
groups with similar reasons for withdrawal
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Gendre 1993 (Continued)
Selective reporting (reporting bias) Unclear risk Although some subgroup analyses were not
prespecified these subgroup analyses would
generally be expected for this type of study
Other bias Low risk The study appears to be free of other
sources of bias
Mahmud 2001
Methods Multicentre study. Described as randomised:Yes Randomisation method described:Yes
Described as double blind:Yes Blind method described:No Follow-ups described:Yes
Participants Inclusion criteria: Age greater than 18. CD of the colitis, ileitis or both. CD in remission
for 1 month prior to randomisation. Remission was defined as assessed by investigator
and by CDAI <150. No steroid use one month prior to study
Interventions Oral 5-ASA vs placebo. Allocation: 167 patients allocated to 5-ASA, and 161 patients
allocated to placebo. Name 5-ASA: Olsalazine. Manufacturer: Kabi Pharmacia. Dose: 2
g per day
Outcomes Relapse measured at: 12 months. Definition of relapse: CDAI > 150 or an increase in
the CDAI score by 60 or more from the baseline score at week 0 or clinical relapse (need
for additional therapy or surgery)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer generated randomiza-
tion”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “the trial was randomised, double-
blind, parallel study”
Quote: “Identical placebos were provided
by Kabi Pharmacia”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Patient and physician assessed outcomes
were blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “More patients in the olsalazine
treated group failed to complete a 52
week treatment period than in the placebo
treated group (olsalazine 65.9% v placebo
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Mahmud 2001 (Continued)
53.4%)”
Quote: “the frequency of intolerable ad-
verse events was higher in the olsalazine
than in the placebo treated group (19.8%
v 6.2%, respectively)”
Selective reporting (reporting bias) Low risk Expected outcomes were reported
Other bias Low risk The study appears to be free of other
sources of bias
Modigliani 1996
Methods Randomised, double-blind, stratified study conducted in 20 Groupe d’Etudes
Thérapeutiques des Affections Inflammatoires Digestives (GETAID) centres, 19 from
France and 1 from Belgium
Participants Patients (N =129) aged 15 years or older with active CD (CDAI > 200)
Specific inclusion criteria: patients with active CD (CDAI > 200); if they were 15 years
or older with CD of the small intestine, recto-colon, or both as documented by barium
radiographs and/or colonoscopy within 12 months before inclusion
Specific exclusion criteria: imminent need for surgery, purely anorectal CD, con-
traindication to corticosteroids, previous hypersensitivity to salicylates or intolerance to
mesalamine, and liver or kidney insufficiency; patients in whom mesalamine had clearly
failed to maintain remissions (i.e., if the attack leading to pre-inclusion had occurred
while they were on mesalamine at a daily dose of > 3 g for more than 2 months)
Interventions Patients with active CD were pre-included in the study and were administered oral
prednisolone (1 mg/kg once a day) for 3-7 weeks
Patients achieving clinical remission within this time frame were included in the trial
and randomly assigned within each centre and stratum to be administered daily either 4
g of mesalamine (Pentasa) or identical placebo tablets
Prednisolone was tapered in steps of 10 mg per 10 days to a dose of 0.5 mg/kg/day and
then in steps of 5 mg per 10 days to complete discontinuation
Outcomes Treatment failure defined as a failure to discontinue steroids (secondary steroid resistance,
steroid dependence, or surgery because of CD) or a relapse (CDAI > 150 and a 100-
point increase above inclusion value and/or need for surgery) during the 1-year follow-
up
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
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Modigliani 1996 (Continued)
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “randomized, double-blind, strati-
fied design”
Quote: “identical tablets containing 500
mg of mesalasmine or placebo were pre-
pared”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Patient and physician assessed outcomes
were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropouts were balanced across treatment
groups with similar reasons for withdrawal
Selective reporting (reporting bias) Low risk Expected outcomes were reported
Other bias Low risk The study appears to be free of other
sources of bias
Prantera 1992
Methods Multicentre study. Described as randomised:Yes Randomisation method described:Yes
Described as double blind:Yes Blind method described:Yes Follow-ups described:Yes
Participants Inclusion criteria: Aged between 18 and 65. CD of the ileum, colon or both. CD in
remission between 3 and 24 months. Remission defined as CDAI<150. No steroid use
3 months prior to study
Interventions Oral 5-ASA vs placebo. Allocation: 64 patients allocated to 5-ASA, and 61 patients
allocated to placebo. Name 5-ASA: Asacol. Manufacturer: Giuliani, Milan. Dose: 2.4 g
/ day
Outcomes Relapse measured at: 12 months. Definition of relapse: CDAI > 150 with an increase of
100 points over the baseline value, confirmed at a second visit 1 week later
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”computer-generated randomiza-
tion list“
Allocation concealment (selection bias) Low risk Quote: ”study medications were centrally
packaged“
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Prantera 1992 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind study
Quote: ”Eligible patientswere randomly al-
located to receive either 5-ASA or identical
placebo tablets for 12 months“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Patient and physician assessed outcomes
were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: ”Eight patients, 5 on 5-ASA and 3
on placebo, were withdrawn from the trial
because of adverse reactions“
Quote: ”One patient was lost to follow-up.
Quote: “Two patients in the 5-ASA group
elected to stop treatment”
Selective reporting (reporting bias) Unclear risk Although some posthoc subgroup analysis
performed were not prespecified these sub-
group analyses would generally be expected
for this type of study
Other bias Low risk The study appears to be free of other
sources of bias
Sutherland 1997
Methods Multicentre study. Described as randomised:Yes Randomisation method described:Yes
Described as double blind:Yes Blind method described:Yes Follow-ups described:Yes
Participants Inclusion criteria: Age greater than 18. CD location restrictions not mentioned. CD in
remission for 1 month, but at least 2 flare-ups within the last 4 years, one within the
last 18 months or a recent resection. Remission defined as CDAI<150 at baseline and
no symptoms within last 30 days. No steroid use within a month of study
Interventions Oral 5-ASA vs placebo. Allocation: 141 patients allocated to 5-ASA, and 152 patients
allocated to placebo. Name 5-ASA:microsphere coated with ethylcellulose,Mesalamine.
Manufacturer: Not provided by authors. Dose: 3 g per day
Outcomes Relapse measured at: 12 months. Definition of relapse: 1st occurrence of a CDAI that
was >150 as well as the absolute value of at least 60 points higher than baseline or where
physician diagnosed a flare-up of disease but a full diary card was not available for the
calculation of the final CDAI
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Sutherland 1997 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: ”computer-generated randomiza-
tion scheme“
Allocation concealment (selection bias) Low risk Quote: ”medication was packaged by the
sponsor and dispensed to each center in
coded identical-appearing boxes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind study
Quote: “Medication was dispensed in bot-
tles containing identical appearing capsules
of either 250 mg mesalamine or placebo”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Patient and physician assessed outcomes
were blinded
Quote: “the statistical analysis was per-
formed using SAS Version 6.04 by a third
party”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Drop-outs balanced across intervention
groups with similar reasons for withdrawal
Quote: “Forty-seven patients were with-
drawn within 28 days after entry into
the study. Twenty-five reported a relapse
(11 mesalamine-treated and 14 placebo-
treated patients), and 22 were withdrawn
for failure to comply with the protocol
(12 mesalmine and 10 placebo-treated pa-
tients”
Selective reporting (reporting bias) Unclear risk Although some subgroup analyses were not
prespecified these analyses would generally
be expected for this type of study
Other bias Low risk The study appears to be free of other
sources of bias
Thomson 1995
Methods Multicentre study. Described as randomised:Yes Randomisation method described:Yes
Described as double blind:Yes Blind method described:Yes Follow-ups described:Yes
Participants Inclusion criteria: Aged between 18 and 70. CD of the ileum, colon or both. CD in
remission but had one period of activity within the previous 28 months. Remission
defined as CDAI<150. No steroid use within month of study
Interventions Oral 5-ASA vs placebo. Allocation: 102 patients allocated to 5-ASA, and 105 patients
allocated to placebo. Name 5-ASA: Claversal / Mesasal. Manufacturer: Smith Kline,
Beecham. Dose: 1.5 g b.d
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Thomson 1995 (Continued)
Outcomes Relapse measured at: 12 months. Definition of relapse: CDAI > 150 with at least a 60-
point increase from the baseline index score
Notes Originally presented as 2 parts ’Colitis or ileocolitis’ and ’Ileitis’
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”randomization with Procplan in
SAS“
Allocation concealment (selection bias) Low risk All studymedicationswere supplied in blis-
ter packets of six tablets which were indis-
tinguishable from one another
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind study
Quote: ”All study medications (mesalazine
and matching placebo) were supplied in
blister packets ....“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Patient and investigator assessed outcomes
were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Drop-outs balanced across intervention
groups with similar reasons for withdrawal
Quote: ”106 patients (51 in the mesalazine
group and 55 in the placebo group) were
withdrawn from the study due to adverse
events
Selective reporting (reporting bias) Low risk Expected outcomes were reported
Other bias Low risk The study appears to be free of other
sources of bias
Wellman 1988
Methods Randomised, double-blind, placebo-controlled study conducted for one year
Participants Patients (N = 66) with Crohn’s disease in remission (CDAI < 150) for at least 3 months
without steroids; diagnosis was confirmed by characteristic endoscopy or radiologic find-
ings
Interventions Study population was randomised to receive mesalazine or placebo in blocks of four
patients
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Wellman 1988 (Continued)
Outcomes Number of relapses was assessed. Adverse reactions were also assessed
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind study
Not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “two patients in the treatment
group were noncompliant...data of these
patients were not evaluated”
Selective reporting (reporting bias) Low risk Expected outcomes were reported
Other bias Low risk The study appears to be free of other
sources of bias
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Anthonisen 1974 Patients were not in remission
Bresci 1991 Not an RCT - alternate allocation
Bresci 1994 Not an RCT - alternate allocation
Brignola 1992 Treatment duration < 6 months (4 months)
Camma 1997 Not an RCT - systematic review
Ewe 1976 Study compared sulphasalazine to placebo, not 5-ASA to placebo or sulphasalazine
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(Continued)
Hanauer 1993 Not an RCT - clinical trial
Lennard-Jones 1977 Wrong comparator - study compared sulphasalazine to placebo, not 5-ASA to placebo or sulphasalazine
Lichtenstein 2009 Not an RCT: open-label, compassionate-use, pre-marketing clinical trial
Luthra 2002 This paper comments on the Mahmud 2001 study
Malchow 1981 Wrong comparator - study compared sulphasalazine to placebo, not 5-ASA to placebo or sulphasalazine
Malchow 1984 Wrong comparator: study compared sulphasalazine to placebo, not 5-ASA to placebo or sulphasalazine
Nakshabendi 1992 Not an RCT - retrospective cohort study
Schreiber 1994 Wrong comparator - study compared 5-ASA to 4-ASA, not 5-ASA to placebo or sulphasalazine
Summers 1979 Wrong comparator: study compared sulphasazline to placebo, not 5-ASA to placebo or 5-ASA to sulphasalazine
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D A T A A N D A N A L Y S E S
Comparison 1. 5-ASA compared to placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Relapse, drop-outs classed as
relapse, grouped by length of
follow-up
12 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 12 months 11 2014 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.91, 1.07]
1.2 24 months 1 161 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.80, 1.23]
1.3 Pediatric 1 132 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.86, 1.33]
2 Sensitivity analysis - Relapse,
drop-outs classed as relapse,
grouped by length of follow-up,
random effects
12 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 12 months 11 2014 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.88, 1.08]
2.2 24 months 1 161 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.80, 1.23]
2.3 Pediatric 1 132 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.86, 1.33]
3 Sensitivity analysis - Relapse,
drop-outs ignored, grouped by
length of follow-up
12 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 12 Months 10 1438 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.79, 1.01]
3.2 24 Months 1 119 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.68, 1.29]
3.3 Pediatric 1 102 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.72, 1.31]
4 Sensitivity analysis - Relapse,
drop-outs ignored, grouped by
length of follow-up, random
effects
12 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 12 Months 10 1438 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.76, 1.05]
4.2 24 Months 1 119 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.68, 1.29]
4.3 Pediatric 1 102 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.72, 1.31]
5 Adverse events 10 1814 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.95, 1.17]
6 Withdrawals due to adverse
events
10 1833 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.88, 1.38]
7 Serious adverse events 3 576 Risk Ratio (M-H, Fixed, 95% CI) 1.43 [0.24, 8.44]
8 Relapse, drop-outs classed as
relapse, grouped by length of
follow-up
11 2014 Odds Ratio (M-H, Fixed, 95% CI) 0.97 [0.81, 1.16]
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Analysis 1.1. Comparison 1 5-ASA compared to placebo, Outcome 1 Relapse, drop-outs classed as relapse,
grouped by length of follow-up.
Review: Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s disease
Comparison: 1 5-ASA compared to placebo
Outcome: 1 Relapse, drop-outs classed as relapse, grouped by length of follow-up
Study or subgroup 5-ASA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 12 months
Anonymous 1990 49/125 52/123 9.7 % 0.93 [ 0.69, 1.25 ]
Arber 1995 12/28 19/31 3.3 % 0.70 [ 0.42, 1.17 ]
Bondesen 1991 29/101 29/101 5.4 % 1.00 [ 0.65, 1.54 ]
De Franchis 1997 42/58 38/59 7.0 % 1.12 [ 0.88, 1.44 ]
Gendre 1993 37/80 43/81 7.9 % 0.87 [ 0.64, 1.19 ]
Mahmud 2001 110/167 86/161 16.3 % 1.23 [ 1.03, 1.48 ]
Modigliani 1996 46/65 50/64 9.4 % 0.91 [ 0.74, 1.11 ]
Prantera 1992 29/64 37/61 7.0 % 0.75 [ 0.53, 1.05 ]
Sutherland 1997 77/141 92/152 16.4 % 0.90 [ 0.74, 1.10 ]
Thomson 1995 85/138 84/148 15.1 % 1.09 [ 0.90, 1.32 ]
Wellman 1988 10/31 14/35 2.4 % 0.81 [ 0.42, 1.55 ]
Subtotal (95% CI) 998 1016 100.0 % 0.98 [ 0.91, 1.07 ]
Total events: 526 (5-ASA), 544 (Placebo)
Heterogeneity: Chi2 = 14.84, df = 10 (P = 0.14); I2 =33%
Test for overall effect: Z = 0.38 (P = 0.70)
2 24 months
Gendre 1993 54/80 55/81 100.0 % 0.99 [ 0.80, 1.23 ]
Subtotal (95% CI) 80 81 100.0 % 0.99 [ 0.80, 1.23 ]
Total events: 54 (5-ASA), 55 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
3 Pediatric
Cezard 2009 50/68 44/64 100.0 % 1.07 [ 0.86, 1.33 ]
Subtotal (95% CI) 68 64 100.0 % 1.07 [ 0.86, 1.33 ]
Total events: 50 (5-ASA), 44 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
0.2 0.5 1 2 5
Favours 5-ASA Favours placebo
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Analysis 1.2. Comparison 1 5-ASA compared to placebo, Outcome 2 Sensitivity analysis - Relapse, drop-
outs classed as relapse, grouped by length of follow-up, random effects.
Review: Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s disease
Comparison: 1 5-ASA compared to placebo
Outcome: 2 Sensitivity analysis - Relapse, drop-outs classed as relapse, grouped by length of follow-up, random effects
Study or subgroup 5-ASA Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 12 months
Anonymous 1990 49/125 52/123 8.1 % 0.93 [ 0.69, 1.25 ]
Arber 1995 12/28 19/31 3.4 % 0.70 [ 0.42, 1.17 ]
Bondesen 1991 29/101 29/101 4.5 % 1.00 [ 0.65, 1.54 ]
De Franchis 1997 42/58 38/59 10.6 % 1.12 [ 0.88, 1.44 ]
Gendre 1993 37/80 43/81 7.7 % 0.87 [ 0.64, 1.19 ]
Mahmud 2001 110/167 86/161 15.2 % 1.23 [ 1.03, 1.48 ]
Modigliani 1996 46/65 50/64 13.4 % 0.91 [ 0.74, 1.11 ]
Prantera 1992 29/64 37/61 6.8 % 0.75 [ 0.53, 1.05 ]
Sutherland 1997 77/141 92/152 13.8 % 0.90 [ 0.74, 1.10 ]
Thomson 1995 85/138 84/148 14.2 % 1.09 [ 0.90, 1.32 ]
Wellman 1988 10/31 14/35 2.2 % 0.81 [ 0.42, 1.55 ]
Subtotal (95% CI) 998 1016 100.0 % 0.98 [ 0.88, 1.08 ]
Total events: 526 (5-ASA), 544 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 14.84, df = 10 (P = 0.14); I2 =33%
Test for overall effect: Z = 0.49 (P = 0.62)
2 24 months
Gendre 1993 54/80 55/81 100.0 % 0.99 [ 0.80, 1.23 ]
Subtotal (95% CI) 80 81 100.0 % 0.99 [ 0.80, 1.23 ]
Total events: 54 (5-ASA), 55 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
3 Pediatric
Cezard 2009 50/68 44/64 100.0 % 1.07 [ 0.86, 1.33 ]
Subtotal (95% CI) 68 64 100.0 % 1.07 [ 0.86, 1.33 ]
Total events: 50 (5-ASA), 44 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
0.2 0.5 1 2 5
Favours 5-ASA Favours placebo
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Analysis 1.3. Comparison 1 5-ASA compared to placebo, Outcome 3 Sensitivity analysis - Relapse, drop-
outs ignored, grouped by length of follow-up.
Review: Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s disease
Comparison: 1 5-ASA compared to placebo
Outcome: 3 Sensitivity analysis - Relapse, drop-outs ignored, grouped by length of follow-up
Study or subgroup 5-ASA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 12 Months
Anonymous 1990 17/93 29/100 9.2 % 0.63 [ 0.37, 1.07 ]
Arber 1995 6/22 15/27 4.4 % 0.49 [ 0.23, 1.05 ]
Bondesen 1991 29/101 29/101 9.6 % 1.00 [ 0.65, 1.54 ]
De Franchis 1997 34/50 29/50 9.6 % 1.17 [ 0.87, 1.59 ]
Mahmud 2001 55/112 59/134 17.7 % 1.12 [ 0.85, 1.46 ]
Modigliani 1996 30/48 24/37 8.9 % 0.96 [ 0.70, 1.33 ]
Prantera 1992 19/54 32/56 10.4 % 0.62 [ 0.40, 0.94 ]
Sutherland 1997 30/94 47/107 14.5 % 0.73 [ 0.50, 1.05 ]
Thomson 1995 33/86 38/102 11.5 % 1.03 [ 0.71, 1.49 ]
Wellman 1988 10/29 14/35 4.2 % 0.86 [ 0.45, 1.64 ]
Subtotal (95% CI) 689 749 100.0 % 0.90 [ 0.79, 1.01 ]
Total events: 263 (5-ASA), 316 (Placebo)
Heterogeneity: Chi2 = 14.94, df = 9 (P = 0.09); I2 =40%
Test for overall effect: Z = 1.75 (P = 0.080)
2 24 Months
Gendre 1993 31/57 36/62 100.0 % 0.94 [ 0.68, 1.29 ]
Subtotal (95% CI) 57 62 100.0 % 0.94 [ 0.68, 1.29 ]
Total events: 31 (5-ASA), 36 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
3 Pediatric
Cezard 2009 29/47 35/55 100.0 % 0.97 [ 0.72, 1.31 ]
Subtotal (95% CI) 47 55 100.0 % 0.97 [ 0.72, 1.31 ]
Total events: 29 (5-ASA), 35 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
0.2 0.5 1 2 5
Favours 5-ASA Favours placebo
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Analysis 1.4. Comparison 1 5-ASA compared to placebo, Outcome 4 Sensitivity analysis - Relapse, drop-
outs ignored, grouped by length of follow-up, random effects.
Review: Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s disease
Comparison: 1 5-ASA compared to placebo
Outcome: 4 Sensitivity analysis - Relapse, drop-outs ignored, grouped by length of follow-up, random effects
Study or subgroup 5-ASA Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 12 Months
Anonymous 1990 17/93 29/100 7.0 % 0.63 [ 0.37, 1.07 ]
Arber 1995 6/22 15/27 3.9 % 0.49 [ 0.23, 1.05 ]
Bondesen 1991 29/101 29/101 9.2 % 1.00 [ 0.65, 1.54 ]
De Franchis 1997 34/50 29/50 13.9 % 1.17 [ 0.87, 1.59 ]
Mahmud 2001 55/112 59/134 15.5 % 1.12 [ 0.85, 1.46 ]
Modigliani 1996 30/48 24/37 13.0 % 0.96 [ 0.70, 1.33 ]
Prantera 1992 19/54 32/56 9.4 % 0.62 [ 0.40, 0.94 ]
Sutherland 1997 30/94 47/107 11.4 % 0.73 [ 0.50, 1.05 ]
Thomson 1995 33/86 38/102 11.3 % 1.03 [ 0.71, 1.49 ]
Wellman 1988 10/29 14/35 5.2 % 0.86 [ 0.45, 1.64 ]
Subtotal (95% CI) 689 749 100.0 % 0.89 [ 0.76, 1.05 ]
Total events: 263 (5-ASA), 316 (Placebo)
Heterogeneity: Tau2 = 0.03; Chi2 = 14.94, df = 9 (P = 0.09); I2 =40%
Test for overall effect: Z = 1.35 (P = 0.18)
2 24 Months
Gendre 1993 31/57 36/62 100.0 % 0.94 [ 0.68, 1.29 ]
Subtotal (95% CI) 57 62 100.0 % 0.94 [ 0.68, 1.29 ]
Total events: 31 (5-ASA), 36 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
3 Pediatric
Cezard 2009 29/47 35/55 100.0 % 0.97 [ 0.72, 1.31 ]
Subtotal (95% CI) 47 55 100.0 % 0.97 [ 0.72, 1.31 ]
Total events: 29 (5-ASA), 35 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
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Analysis 1.5. Comparison 1 5-ASA compared to placebo, Outcome 5 Adverse events.
Review: Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s disease
Comparison: 1 5-ASA compared to placebo
Outcome: 5 Adverse events
Study or subgroup 5-ASA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Anonymous 1990 17/125 21/123 7.1 % 0.80 [ 0.44, 1.44 ]
Arber 1995 1/28 1/31 0.3 % 1.11 [ 0.07, 16.88 ]
Cezard 2009 32/68 29/64 10.1 % 1.04 [ 0.72, 1.50 ]
De Franchis 1997 1/58 0/59 0.2 % 3.05 [ 0.13, 73.39 ]
Gendre 1993 7/80 10/81 3.3 % 0.71 [ 0.28, 1.77 ]
Mahmud 2001 65/167 44/160 15.1 % 1.42 [ 1.03, 1.94 ]
Prantera 1992 5/64 7/61 2.4 % 0.68 [ 0.23, 2.03 ]
Sutherland 1997 120/141 141/152 45.7 % 0.92 [ 0.85, 1.00 ]
Thomson 1995 55/138 48/148 15.6 % 1.23 [ 0.90, 1.68 ]
Wellman 1988 4/31 0/35 0.2 % 10.13 [ 0.57, 180.85 ]
Total (95% CI) 900 914 100.0 % 1.05 [ 0.95, 1.17 ]
Total events: 307 (5-ASA), 301 (Placebo)
Heterogeneity: Chi2 = 19.90, df = 9 (P = 0.02); I2 =55%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours 5-ASA Favours placebo
42Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s disease (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.6. Comparison 1 5-ASA compared to placebo, Outcome 6 Withdrawals due to adverse events.
Review: Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s disease
Comparison: 1 5-ASA compared to placebo
Outcome: 6 Withdrawals due to adverse events
Study or subgroup 5-ASA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Anonymous 1990 8/125 5/123 4.3 % 1.57 [ 0.53, 4.68 ]
Arber 1995 1/28 1/31 0.8 % 1.11 [ 0.07, 16.88 ]
Cezard 2009 2/68 1/64 0.9 % 1.88 [ 0.17, 20.26 ]
De Franchis 1997 0/58 0/59 Not estimable
Gendre 1993 7/80 10/81 8.5 % 0.71 [ 0.28, 1.77 ]
Mahmud 2001 35/167 11/160 9.6 % 3.05 [ 1.60, 5.79 ]
Modigliani 1996 0/48 1/37 1.4 % 0.26 [ 0.01, 6.17 ]
Prantera 1992 5/64 3/61 2.6 % 1.59 [ 0.40, 6.36 ]
Sutherland 1997 40/141 58/152 47.8 % 0.74 [ 0.53, 1.04 ]
Thomson 1995 29/138 29/148 24.0 % 1.07 [ 0.68, 1.70 ]
Total (95% CI) 917 916 100.0 % 1.11 [ 0.88, 1.38 ]
Total events: 127 (5-ASA), 119 (Placebo)
Heterogeneity: Chi2 = 17.69, df = 8 (P = 0.02); I2 =55%
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 5-ASA compared to placebo, Outcome 7 Serious adverse events.
Review: Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s disease
Comparison: 1 5-ASA compared to placebo
Outcome: 7 Serious adverse events
Study or subgroup 5-ASA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cezard 2009 1/68 1/64 50.2 % 0.94 [ 0.06, 14.73 ]
De Franchis 1997 0/58 0/59 Not estimable
Mahmud 2001 2/167 1/160 49.8 % 1.92 [ 0.18, 20.93 ]
Total (95% CI) 293 283 100.0 % 1.43 [ 0.24, 8.44 ]
Total events: 3 (5-ASA), 2 (Placebo)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.39 (P = 0.70)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 5-ASA compared to placebo, Outcome 8 Relapse, drop-outs classed as relapse,
grouped by length of follow-up.
Review: Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s disease
Comparison: 1 5-ASA compared to placebo
Outcome: 8 Relapse, drop-outs classed as relapse, grouped by length of follow-up
Study or subgroup 5-ASA Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Anonymous 1990 49/125 52/123 13.2 % 0.88 [ 0.53, 1.46 ]
Arber 1995 12/28 19/31 4.3 % 0.47 [ 0.17, 1.34 ]
Bondesen 1991 29/101 29/101 8.6 % 1.00 [ 0.54, 1.84 ]
De Franchis 1997 42/58 38/59 4.3 % 1.45 [ 0.66, 3.18 ]
Gendre 1993 37/80 43/81 9.5 % 0.76 [ 0.41, 1.41 ]
Mahmud 2001 110/167 86/161 12.4 % 1.68 [ 1.08, 2.63 ]
Modigliani 1996 46/65 50/64 6.1 % 0.68 [ 0.31, 1.51 ]
Prantera 1992 29/64 37/61 8.6 % 0.54 [ 0.26, 1.09 ]
Sutherland 1997 77/141 92/152 16.6 % 0.78 [ 0.49, 1.25 ]
Thomson 1995 85/138 84/148 12.9 % 1.22 [ 0.76, 1.96 ]
Wellman 1988 10/31 14/35 3.7 % 0.71 [ 0.26, 1.97 ]
Total (95% CI) 998 1016 100.0 % 0.97 [ 0.81, 1.16 ]
Total events: 526 (5-ASA), 544 (Placebo)
Heterogeneity: Chi2 = 14.95, df = 10 (P = 0.13); I2 =33%
Test for overall effect: Z = 0.38 (P = 0.70)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Randomised patients with unknown outcome
Study Total Unknown - n(%) 5-ASA unknown - n(%) Placebo unknown - n(%)
Anonymous 1990 55 (22%) 23 (19%) 32 (26%)
Arber 1995 10 (17%) 6 (21%) 4 (13%)
Cezard 2009 30 (23%) 21 (31%) 9 (14%)
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Table 1. Randomised patients with unknown outcome (Continued)
De Franchis 1997 17 (14%) 8 (14%) 9 (15%)
Gendre 1993 (Eng) 42 (26%) 23 (29%) 19 (23%)
Mahmud 2001 82 (25%) 55 (33%) 27 (17%)
Modigliani 1996 44 (34%) 17 (26%) 27 (42%)
Prantera 1992 15 (12%) 10 (16%) 5 (8%)
Sutherland 1997 92 (31%) 47 (33%) 45 (30%)
Thompson 1995 98 (34%) 52 (38%) 46 (31%)
Wellman 1988 2 (3%) 2 (6%) 0 (0%)
A P P E N D I C E S
Appendix 1. MEDLINE, EMBASE, CENTRAL and Cochrane IBD Specialized Register Search
Strategies
MEDLINE
1. random$.tw.
2. factorial$.tw.
3. (crossover$ or cross over$ or cross-over$).tw.
4. placebo$.tw.
5. single blind.mp.
6. double blind.mp.
7. triple blind.mp.
8. (singl$ adj blind$).tw.
9. (double$ adj blind$).tw.
10. (tripl$ adj blind$).tw.
11. assign$.tw.
12. allocat$.tw.
13. crossover procedure/
14. double blind procedure/
15. single blind procedure/
16. triple blind procedure/
17. randomized controlled trial/
18. or/1-17
19. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)
20. 18 not 19
21. (crohn).mp.
22. exp Crohn disease/
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23. ileitis.mp.
24. (inflammatory bowel disease* or IBD).mp.
25. or/21-24
26. 20 and 25
27. 5-aminosalicylic acid.mp.
28. 5-ASA.mp.
29. Mesalazine.mp. or mesalamine.mp.
30. Sulfasalazine.mp.
31. balsalazide.mp.
32. osalazine.mp.
33. (aminosalicylic or aminosalicylate).mp.
34. or/26-33
35. 26 and 34
EMBASE
1. random$.tw.
2. factorial$.tw.
3. (crossover$ or cross over$ or cross-over$).tw.
4. placebo$.tw.
5. single blind.mp.
6. double blind.mp.
7. triple blind.mp.
8. (singl$ adj blind$).tw.
9. (double$ adj blind$).tw.
10. (tripl$ adj blind$).tw.
11. assign$.tw.
12. allocat$.tw.
13. crossover procedure/
14. double blind procedure/
15. single blind procedure/
16. triple blind procedure/
17. randomized controlled trial/
18. or/1-17
19. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)
20. 18 not 19
21. (crohn).mp.
22. exp Crohn disease/
23. ileitis.mp.
24. (inflammatory bowel disease* or IBD).mp.
25. or/21-24
26. 20 and 25
27. 5-aminosalicylic acid.mp.
28. 5-ASA.mp.
29. Mesalazine.mp. or mesalamine.mp.
30. Sulfasalazine.mp.
31. balsalazide.mp.
32. osalazine.mp.
33. (aminosalicylic or aminosalicylate).mp.
34. or/26-33
35. 26 and 34
CENTRAL
#1 MeSH descriptor: [Crohn Disease] explode all trees
#2 Crohn
#3 ileitis
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#4 inflammatory bowel disease
#5 IBD
#6 #1 or #2 or #3 or #4 or #5
#7 (5-aminosalicylic acid) OR (5-ASA) OR (mesalazine) OR (mesalamine) OR (sulfasalazine) OR (balsalazide) OR (osalazine) OR
(aminosalicylic) OR (aminosalicylate)
#8 #6 and #7
Cochrane IBD Group Specialized Register
1. (Crohn OR ileitis OR inflammatory bowel disease OR IBD) (ti/ab)
2. (5-aminosalicylic acid) OR (5-ASA) OR (mesalazine) OR (mesalamine) OR (sulfasalazine) OR (balsalazide) OR (osalazine) OR
(aminosalicylic) OR (aminosalicylate)
3. 1 AND 2
WH A T ’ S N E W
Last assessed as up-to-date: 8 June 2016.
Date Event Description
8 June 2016 New citation required but conclusions have not changed Updated review with two new authors. Conclusions did
not change
8 June 2016 New search has been performed New literature search performed on 8 June 2016. Five new
studies were added
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal [∗administration & dosage]; Crohn Disease [∗prevention & control];
Mesalamine [∗administration & dosage]; Remission Induction; Secondary Prevention; Sulfasalazine [administration & dosage]
MeSH check words
Humans
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